Sector
PharmaceuticalsOpen
₹2,445Prev. Close
₹2,481.6Turnover(Lac.)
₹11,594.63Day's High
₹2,595Day's Low
₹2,434.852 Week's High
₹3,054.852 Week's Low
₹1,901.05Book Value
₹343.9Face Value
₹1Mkt Cap (₹ Cr.)
1,06,516.52P/E
52.93EPS
46.87Divi. Yield
0Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.
The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.
The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.
According to the National Cancer Registry Programme, cancer is expected to cause 29.8 million DALYs by 2025, making it a serious health issue in India.
The issue price includes a premium of ₹2,519 per share, aggregating a total of ₹2,999.99 crore.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 40.06 | 40.06 | 40.06 | 40.06 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 9,583.75 | 7,743.85 | 6,500.39 | 4,694.21 |
Net Worth | 9,623.81 | 7,783.91 | 6,540.45 | 4,734.27 |
Minority Interest |
No Record Found
No Record Found
No Record Found
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 10,334.77 | 8,749.43 | 7,781.56 | 6,214.43 | 5,865.23 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 10,334.77 | 8,749.43 | 7,781.56 | 6,214.43 | 5,865.23 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 296.07 | 140.99 | 210.48 | 182.63 | 121.96 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,742.2 | 151.67 | 4,18,132.11 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,618.55 | 81.25 | 1,49,254.4 | 518 | 0.53 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,439.5 | 24.95 | 1,16,122.78 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,207.7 | 59.46 | 1,08,471.97 | 485 | 0.87 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,481.6 | 52.93 | 1,02,347.53 | 416.38 | 0 | 2,396.57 | 334.18 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Wholetime Director
RAMESH CHAND JUNEJA
Vice Chairman & M.D.
RAJEEV JUNEJA
Whole Time Director & CEO
SHEETAL ARORA
Independent Director
TILOKCHAND PUNAMCHAND OSTWAL
Independent Director
Bharat Anand
Whole-time Director
SATISH KUMAR SHARMA
Independent Director
Vivek Kalra
Independent Director
Vijaya Sampath
Company Sec. & Compli. Officer
Hitesh Kumar Jain
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Mankind Pharma Ltd
Summary
Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name Mankind Pharma Private Limited, by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to Mankind Pharma Limited and the RoC issued a fresh Certificate of Incorporation on April 13, 2006.The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory. In 2004, the Company entered the chronic pharmaceutical segment with the launch of Amlokind tablets and Glimestar tablets amongst others. It set up their first manufacturing facility at Paonta Sahib, in Himachal Pradesh during year 2005. It entered the ophthalmic pharmaceutical segment with the launching of Lubistar Eye Drops and Tobastar Eye Drops. In 2007, the Company entered the consumer healthcare segment with the launch of Manforce brand and have since established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineralsupplements and anti-acne preparations categories. It entered into the business of animal h
Read More
The Mankind Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2581.8 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Mankind Pharma Ltd is ₹106516.52 Cr. as of 03 Feb ‘25
The PE and PB ratios of Mankind Pharma Ltd is 52.93 and 7.42 as of 03 Feb ‘25
The 52-week high/low is the highest and lowest price at which a Mankind Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Mankind Pharma Ltd is ₹1901.05 and ₹3054.8 as of 03 Feb ‘25
Mankind Pharma Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at 21.28%, 6 Month at 23.79%, 3 Month at -7.43% and 1 Month at -13.86%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.